VERTEX PHARMACEUTICALS ($VRTX) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of $4.76 per share, missing estimates of $4.88 by $0.12. The company also reported revenue of $3,440,800,000, missing estimates of $3,485,765,503 by $-44,965,503.
Stock price change since market close: +1.24%
You can see Quiver Quantitative's $VRTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VERTEX PHARMACEUTICALS Insider Trading Activity
VERTEX PHARMACEUTICALS insiders have traded $VRTX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- CARMEN BOZIC (EVP and CMO) has made 0 purchases and 5 sales selling 14,411 shares for an estimated $6,516,733.
- DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) sold 1,541 shares for an estimated $799,779
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) sold 1,500 shares for an estimated $787,485
- JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 1,656 shares for an estimated $780,489.
- SANGEETA N. BHATIA sold 318 shares for an estimated $134,746
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
VERTEX PHARMACEUTICALS Hedge Fund Activity
We have seen 888 institutional investors add shares of VERTEX PHARMACEUTICALS stock to their portfolio, and 735 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 6,517,600 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,237,487,448
- INVESCO LTD. added 5,481,995 shares (+214.1%) to their portfolio in Q2 2026, for an estimated $2,723,071,376
- FRANKLIN RESOURCES INC added 2,796,121 shares (+507.3%) to their portfolio in Q2 2026, for an estimated $1,388,917,184
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,041,282 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,013,966,007
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,635,327 shares (-7.7%) from their portfolio in Q2 2026, for an estimated $812,315,980
- VICTORY CAPITAL MANAGEMENT INC removed 1,183,614 shares (-35.3%) from their portfolio in Q2 2026, for an estimated $587,936,582
- ALLIANCEBERNSTEIN L.P. removed 891,471 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $442,820,389
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
VERTEX PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 08/26.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
VERTEX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 2 analysts offer price targets for $VRTX in the last 6 months, with a median target of $460.0.
Here are some recent targets:
- Brian Skorney from Baird set a target price of $350.0 on 07/07/2026
- Brian Abrahams from RBC Capital set a target price of $570.0 on 07/07/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
